Improvements in glycemic control through non-insulin-dependent pathways with SGLT2 inhibitors are also important as an add-on treatment for type 1 DM, as improved glycemic control can reduce end-organ complications in DM patients. This evidence concerns the gene INS and diabetes mellitus.